Rising Diabetes Prevalence Boosts Growth In The Proliferative Diabetic Retinopathy (PDR) Market: A Key Catalyst Accelerating Global Proliferative Diabetic Retinopathy (PDR) Market Growth in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Proliferative Diabetic Retinopathy (PDR) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for proliferative diabetic retinopathy (pdr) has experienced swift expansion lately, projected to increase from $2.42 billion in 2024 to reach $2.69 billion by 2025, reflecting an 11.3% compound annual growth rate (CAGR); this past expansion phase was fueled by the increasing incidence of diabetes, shifts toward detrimental lifestyle habits and poor dietary choices, supportive government programs, and an escalating count of vision impairments linked to diabetes.

Proliferative Diabetic Retinopathy (PDR) Market Size Forecast: What's the Projected Valuation by 2029?
Anticipating substantial expansion over the foroming years, the market segment pertaining to proliferative diabetic retinopathy is projected to reach a valuation of $4.03 billion by 2029, demonstrating a compound annual growth rate of 10.6%; this upward trajectory is fueled by several key factors, including the increasing global aging demographic, heightened public knowledge and educational efforts surrounding diabetes, augmented financial backing for research endeavors, and a growing preference for multifaceted treatment regimens. Furthermore, significant movements shaping this market over the projection timeframe encompass progress in diagnostic instrumentation, novel developments in therapeutic methodologies, the integration of artificial intelligence for the purpose of early identification, breakthroughs in the field of gene therapy, and improvements in sophisticated retinal imaging techniques.

View the full report here:
https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

What Are the Drivers Transforming the Proliferative Diabetic Retinopathy (PDR) Market?
The increasing incidence of diabetes is projected to fuel the future expansion of the proliferative diabetic retinopathy (PDR) market. Diabetes, defined by persistently high blood sugar concentrations, serves as the primary underlying cause for proliferative diabetic retinopathy, a condition amenable to numerous therapies aimed at halting retinal deterioration and maintaining sight. As an illustration of this escalating issue, governmental findings from the UK's National Health Service indicated a substantial surge in diabetes cases among those under the age of forty, climbing from 173,166 in 2022 to 216,440 by 2023 in June 2024, underscoring a worrying acceleration of diabetes among younger demographics, consequently propelling the demand within the PDR market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

What Long-Term Trends Will Define the Future of the Proliferative Diabetic Retinopathy (PDR) Market?
Major companies operating in the proliferative diabetic retinopathy market are consistently working on developing innovative therapies to improve treatment outcomes, lessen patient burden, and enhance overall efficacy. For instance, in June 2022, Biogen, a US-based biotechnology company, in collaboration with Samsung Bioepis, a South Korea-based biotech firm, launched Byooviz (ranibizumab-nuna), the first ophthalmology biosimilar in the US. This product is used to treat conditions such as diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.

Which Segments in the Proliferative Diabetic Retinopathy (PDR) Market Offer the Most Profit Potential?
The proliferative diabetic retinopathy (pdr)market covered in this report is segmented -

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy; Intraocular Steroids; Laser Surgery; Vitrectomy
2) By Mode of Administration: Injectables; Oral; Other Mode Of Administrations
3) By Application: Hospitals; Clinics; Other Applications

Subsegments:
1) By Anti-VEGF Therapy: Aflibercept; Ranibizumab; Bevacizumab
2) By Intraocular Steroids: Triamcinolone Acetonide; Dexamethasone Implant; Fluocinolone Acetonide
3) By Laser Surgery: Focal Laser Photocoagulation; Panretinal Laser Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy; Anterior Vitrectomy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp

Which Firms Dominate the Proliferative Diabetic Retinopathy (PDR) Market by Market Share and Revenue in 2025?
Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

Which Regions Offer the Highest Growth Potential in the Proliferative Diabetic Retinopathy (PDR) Market?
North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.